Newron Pharmaceuticals (NWPHF) News Today $9.36 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Rises By 29.8%Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF - Get Free Report) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 124,900 shares, a growth of 29.8% from the September 15th total of 96,200 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 1,249.0 days.October 13, 2024 | marketbeat.comNewron presents H1 2024 results and provides business updateSeptember 19, 2024 | finance.yahoo.comEQS-News: Newron presents H1 2024 results and provides business updateSeptember 19, 2024 | markets.businessinsider.comNewron presents H1 2024 results and provides business updateSeptember 19, 2024 | businesswire.comNewron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Sees Significant Growth in Short InterestNewron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF - Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 95,900 shares, a growth of 73.1% from the August 15th total of 55,400 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.September 14, 2024 | marketbeat.comWe Might See A Profit From Newron Pharmaceuticals S.p.A. (VTX:NWRN) SoonAugust 20, 2024 | finance.yahoo.comNewron Pharmaceuticals SpA (NWRN)July 25, 2024 | investing.comNewron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia PatientsMay 13, 2024 | finance.yahoo.comData from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)April 8, 2024 | finance.yahoo.comNewron Presents 2023 Financial Results and Provides 2024 OutlookMarch 19, 2024 | finance.yahoo.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreementMarch 15, 2024 | finance.yahoo.comBreakeven Is Near for Newron Pharmaceuticals S.p.A. (VTX:NWRN)March 13, 2024 | finance.yahoo.comNewron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)January 4, 2024 | finance.yahoo.comNewron enrols all subjects in schizophrenia treatment trialJanuary 2, 2024 | msn.comEQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with EvenamideDecember 29, 2023 | markets.businessinsider.comNewron Pharmaceuticals SpA NWRNDecember 13, 2023 | morningstar.comNewron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry CriteriaOctober 9, 2023 | finance.yahoo.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36 th European College of Neuropsychopharmacology CongressOctober 4, 2023 | businesswire.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology CongressOctober 4, 2023 | finance.yahoo.comEQS-News: Newron appoints Margarita Chavez as board advisorOctober 2, 2023 | markets.businessinsider.comNewron Appoints Margarita Chavez as Board AdvisorOctober 2, 2023 | finance.yahoo.comNewron Announces H1 2023 Results and Provides R&D UpdateAugust 4, 2023 | finance.yahoo.comEQS-News: Newron announces H1 2023 results and provides R&D updateAugust 4, 2023 | markets.businessinsider.comInvesting in Newron Pharmaceuticals (VTX:NWRN) a year ago would have delivered you a 187% gainJune 15, 2023 | finance.yahoo.comEQS-News: Newron announces Senior Management Team changesMay 2, 2023 | markets.businessinsider.comNewron announces Senior Management Team changesMay 2, 2023 | uk.finance.yahoo.comAnalysts Expect Newron Pharmaceuticals S.p.A. (VTX:NWRN) To Breakeven SoonApril 27, 2023 | finance.yahoo.comNewron announces AGM 2023 resultsApril 18, 2023 | uk.finance.yahoo.comEQS-News: Newron announces AGM 2023 resultsApril 18, 2023 | markets.businessinsider.comEQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 28, 2023 | markets.businessinsider.comNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 28, 2023 | uk.finance.yahoo.comEQS-News: Newron to present at the 31st European Congress of PsychiatryMarch 17, 2023 | markets.businessinsider.comNewron announces 2022 financial results and provides outlook for 2023March 14, 2023 | uk.finance.yahoo.comNewron: Managing India’s Next-gen of Modern SchoolsFebruary 13, 2023 | msn.comNewron Pharmaceuticals (VTX:NWRN) soars 117% this week, taking one-year gains to 104%January 6, 2023 | ca.finance.yahoo.comNewron Pharmaceuticals S.p.A.December 22, 2022 | wsj.comAnalysts Expect Breakeven For Newron Pharmaceuticals S.p.A. (VTX:NWRN) Before LongOctober 31, 2022 | finance.yahoo.comNewron provides H1 2022 results and updates on R&D and business activitiesSeptember 15, 2022 | uk.finance.yahoo.comNewron provides H1 2022 results and updates on R&D and business activitiesSeptember 15, 2022 | uk.finance.yahoo.comDGAP-News: Newron provides H1 2022 results and updates on R&D and business activitiesSeptember 15, 2022 | markets.businessinsider.comDGAP-News: Newron extends Senior Management team and strengthens commitment to ESGJuly 1, 2022 | markets.businessinsider.comNewron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of NeuropsychopharmacologyJune 7, 2022 | finance.yahoo.comDGAP-News: Newron announces 2021 financial results and provides outlook for 2022March 15, 2022 | markets.businessinsider.comNewron Pharmaceuticals Spa. (NWPHF)January 19, 2022 | nasdaq.comChange in Newron Board of DirectorsDecember 1, 2021 | uk.finance.yahoo.comEQS-Adhoc: Change in Newron Board of DirectorsDecember 1, 2021 | markets.businessinsider.comDGAP-News: Change in Newron Board of DirectorsDecember 1, 2021 | markets.businessinsider.comNewron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)October 18, 2021 | finance.yahoo.comNewron Announces Half-Year 2021 ResultsSeptember 16, 2021 | finance.yahoo.comNewron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)September 6, 2021 | finance.yahoo.com Get Newron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. Email Address NASDAQ small cap that could be gearing up for a massive short squeeze. (Ad)A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm! See how this NASDAQ Bio-tech is offering viable solutions NWPHF Media Mentions By Week NWPHF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NWPHF News Sentiment▼0.000.45▲Average Medical News Sentiment NWPHF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NWPHF Articles This Week▼00▲NWPHF Articles Average Week Get Newron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABIVAX Société Anonyme News Today Ironwood Pharmaceuticals News Today Astria Therapeutics News Today Y-mAbs Therapeutics News Today Avid Bioservices News Today CureVac News Today Stoke Therapeutics News Today Entrada Therapeutics News Today Tango Therapeutics News Today Acelyrin News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NWPHF) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Newron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
